Table 7.
Burden of disease of RR CLL and five-year budget impact with and without Ibrutinib (million Japanese Yen)
| Cost of illness RR CLL (2015) | Cost of illness RR CLL per patient per year | Total Cost RR CLL w/o ibrutinib (2016–2020) | Total Costs RR CLL with ibrutinib (2016–2020) | RR CLL with ibrutinib (2020) | RR CLL with ibrutinib per patient per year (2020) | |
|---|---|---|---|---|---|---|
| Anticancer drug acquisition costs | 1370.52 | 2.60 | 6852.60 | 22,474.40 | 5932.26 | 7.70 |
| Administration costs | 174.62 | 0.33 | 867.12 | 639.85 | 119.26 | 0.15 |
| Toxicity related costs | 18.59 | 0.04 | 92.97 | 83.62 | 17.66 | 0.02 |
| Total (5 years) | 7813.69 | 23,197.89 | ||||
| Total annual average | 1562.74 | 2.96 | 1562.74 | 4639.57 | 6069.15 | 7.88 |
CLL chronic lymphocytic leukemia, RR CLL relapsed/refractory chronic lymphocytic leukemia